These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8750152)

  • 1. Randomised study using IFN-alpha versus IFN-alpha plus coumarin and cimetidine for treatment of advanced renal cell cancer.
    Sagaster P; Micksche M; Flamm J; Ludwig H
    Ann Oncol; 1995 Dec; 6(10):999-1003. PubMed ID: 8750152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cimetidine and coumarin therapy of renal cell carcinoma. A pilot study.
    Kokron O; Maca S; Gasser G; Schmidt PR
    Oncology; 1991; 48(2):102-6. PubMed ID: 1997930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Impact of immunochemotherapy on survival of patients with metastatic renal cell carcinoma. A retrospective study comparing interferon-alpha-2a/vinblastine versus interferon-alpha-2a/interleukin-2/5-fluorouracil].
    May M; Helke C; Bock M; Hoschke B
    Urologe A; 2004 Sep; 43(9):1111-9. PubMed ID: 15232686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
    Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
    Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters.
    Schwaab T; Heaney JA; Schned AR; Harris RD; Cole BF; Noelle RJ; Phillips DM; Stempkowski L; Ernstoff MS
    J Urol; 2000 Apr; 163(4):1322-7. PubMed ID: 10737537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of high-dose cimetidine and the combination 5-fluorouracil, interferon alpha-2A, and leucovorin in advanced renal cell adenocarcinoma.
    Creagan ET; Veeder MH; Suman VJ; Burch PA; Maples WJ; Schaefer PL; Pfeifle DM; Dalton RJ; Hatfield AK; Poon MA
    Am J Clin Oncol; 1998 Oct; 21(5):475-8. PubMed ID: 9781603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is interferon with or without vinblastine the "treatment of choice" in metastatic renal cell carcinoma? The Norwegian Radium Hospital's experience 1983-1986.
    Fosså SD
    Semin Surg Oncol; 1988; 4(3):178-83. PubMed ID: 3055161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of metastatic renal cell carcinoma with constant-rate floxuridine infusion plus recombinant alpha 2b-interferon.
    Falcone A; Cianci C; Pfanner E; Ricci S; Lencioni M; Brunetti I; Giulianotti PC; Vannucci L; Mosca F; Conte PF
    Ann Oncol; 1996 Aug; 7(6):601-5. PubMed ID: 8879374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer.
    Marincola FM; White DE; Wise AP; Rosenberg SA
    J Clin Oncol; 1995 May; 13(5):1110-22. PubMed ID: 7738617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
    Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
    J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective randomized trial of natural interferon-alpha versus natural interferon-alpha plus cimetidine in advanced renal cell carcinoma with pulmonary metastasis.
    Kinouchi T; Sakamoto J; Tsukamoto T; Akaza H; Kubota Y; Ozono S; Kanetake H; Taguchi T; Kotake T;
    J Cancer Res Clin Oncol; 2006 Aug; 132(8):499-504. PubMed ID: 16586071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma.
    Motzer RJ; Rakhit A; Thompson JA; Nemunaitis J; Murphy BA; Ellerhorst J; Schwartz LH; Berg WJ; Bukowski RM
    J Interferon Cytokine Res; 2001 Apr; 21(4):257-63. PubMed ID: 11359657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of chemotherapy and recombinant alpha-interferon in advanced non-small cell lung cancer. Multicentric Randomized FONICAP Trial Report. The Italian Lung Cancer Task Force.
    Ardizzoni A; Salvati F; Rosso R; Bruzzi P; Rubagotti A; Pennucci MC; Mariani GL; De Marinis F; Pallotta G; Antilli A
    Cancer; 1993 Nov; 72(10):2929-35. PubMed ID: 8221559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival in renal cell carcinoma-a randomized evaluation of tamoxifen vs interleukin 2, alpha-interferon (leucocyte) and tamoxifen.
    Henriksson R; Nilsson S; Colleen S; Wersäll P; Helsing M; Zimmerman R; Engman K
    Br J Cancer; 1998 Apr; 77(8):1311-7. PubMed ID: 9579838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preliminary results of the alternating administration of natural interferon-alpha and recombinant interferon-gamma for metastatic renal cell carcinoma.
    Fujii A; Yui-En K; Ono Y; Yamamoto H; Gohji K; Takenaka A
    BJU Int; 1999 Sep; 84(4):399-404. PubMed ID: 10468752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-alpha does not improve the antineoplastic efficacy of high-dose infusional 5-fluorouracil plus folinic acid in advanced colorectal cancer. First results of a randomized multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO).
    Köhne CH; Wilke H; Hecker H; Schöffski P; Käufer C; Rauschecker H; Andreesen R; Ohl U; Lange HJ; Klaassen U
    Ann Oncol; 1995 May; 6(5):461-6. PubMed ID: 7669711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase II/III trial of interferon Alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell Carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951).
    Aass N; De Mulder PH; Mickisch GH; Mulders P; van Oosterom AT; van Poppel H; Fossa SD; de Prijck L; Sylvester RJ
    J Clin Oncol; 2005 Jun; 23(18):4172-8. PubMed ID: 15961764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma. The EORTC Genitourinary Group.
    De Mulder PH; Oosterhof G; Bouffioux C; van Oosterom AT; Vermeylen K; Sylvester R
    Br J Cancer; 1995 Feb; 71(2):371-5. PubMed ID: 7841054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stratification by risk factors predicts survival on the active treatment arm in a randomized phase II study of interferon-gamma plus/minus interferon-alpha in advanced renal cell carcinoma (E6890).
    Dutcher JP; Fine JP; Krigel RL; Murphy BA; Schaefer PL; Ernstoff MS; Loehrer PJ
    Med Oncol; 2003; 20(3):271-81. PubMed ID: 14514977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
    Dutcher JP; Logan T; Gordon M; Sosman J; Weiss G; Margolin K; Plasse T; Mier J; Lotze M; Clark J; Atkins M
    Clin Cancer Res; 2000 Sep; 6(9):3442-50. PubMed ID: 10999727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.